SLS (SELLAS Life Sciences Group) GF Value : $0.00 (As of Mar. 26, 2025)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group GF Value?

As of today (2025-03-26), SELLAS Life Sciences Group's share price is $1.22. SELLAS Life Sciences Group's GF Value is $0.00. Therefore, SELLAS Life Sciences Group's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes SELLAS Life Sciences Group is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

SELLAS Life Sciences Group (NAS:SLS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

SELLAS Life Sciences Group's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.22	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group GF Value Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08